Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02268474
Other study ID # C-14-EV04
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2014
Est. completion date August 2015

Study information

Verified date January 2023
Source Cutera Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea. Subjects will receive laser treatments and will be followed at 6 weeks post-final laser treatment.


Description:

The purpose of this study is to evaluate the safety and efficacy of the 532nm KTP laser within the Cutera® Excel V system for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea as compared to a 595nm Pulse Dye Laser. The objectives of this study are: 1) To evaluate and compare the safety and efficacy of the laser treatments for Erythematotelangiectatic Rosacea and Papulopustular Rosacea at 6 weeks post final laser treatment.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date August 2015
Est. primary completion date August 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria: 1. Females or Males, 20 to 80 years of age (inclusive). 2. Fitzpatrick Skin Type I - III. 3. Clinical diagnosis of Erythematotelangiectatic Rosacea and Papulopustular Rosacea. 4. Willing to refrain from using systemic corticosteroids or retinoids; or topical corticosteroids or retinoids on the treated area. 5. Must be able to read, understand and sign the Informed Consent Form. 6. Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions. 7. Wiling to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the face every day for the duration of the study, including the follow-up period. 8. Willingness to have digital photographs taken of the face. 9. Agree not to undergo any other procedure for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea during the study. 10. Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study. Exclusion Criteria: 1. History of prior laser or light based procedures for the face within 6 months of study participation. 2. Fitzpatrick Skin Type IV - VI. 3. Pregnant and/or breastfeeding. 4. Subject is less than 20 years of age or greater than 80 years of age. 5. Having an infection, dermatitis or rash in the treatment area. 6. Suffering from significant concurrent illness, such as diabetes mellitus, cardiovascular disease, uncontrolled hypertension, or pertinent neurological disorders. 7. History of keloid formation, hypertrophic scarring or of abnormal wound healing. 8. History of immunosuppression/immune deficiency disorders such as psoriasis, eczema, vitiligo, or currently using immunosuppressive medications. 9. Malignant tumors in the target area or history of a malignant skin disease. 10. History of fibromyalgia. 11. History of connective tissue disease, such as systemic lupus erythematosus or scleroderma. 12. Having a known anticoagulative condition or taking prescription anticoagulation medications. 13. History of seizure disorders due to light. 14. Any current use of medication that is known to increase sensitivity to light, such as tetracycline. 15. Having a history of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area, unless treatment is conducted following a prophylactic regimen. 16. Having undergone any surgery in the treatment area within 6 months of treatment (or more if skin has not healed completely). 17. History of radiation to the head, neck and/or upper chest. 18. History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation. 19. Undergoing systemic chemotherapy for the treatment of cancer. 20. Systemic use of retinoid such as isotretinoin and/or corticosteroid within 6 months. 21. Topical use of retinoid and/or corticosteroid within 4 weeks of study participation. 22. Any use of gold therapy for disorders such as rheumatologic disease or lupus. 23. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study. 24. Current smoker or history of smoking within 12 months of study participation. 25. Participation in a study of another device or drug within 6 months prior to enrollment or during the study. 26. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Study Design


Intervention

Device:
532nm KTP Laser vs 595nm Pulse Dye Laser
Intervention for the Cutera Excel V system is to cease treatment to any subject that is experiencing any adverse reaction.

Locations

Country Name City State
United States Miami Dermatology & Laser Institute Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
Cutera Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea Measured for each treatment arm based on blinded physician assessment of subject photographs using the Physician's Global Assessment Scale (min=0; max=4) Higher scores mean better improvement 0 = 0% Improvement (None)
= < 25% Improvement (Mild)
= 26 to 50% Improvement (Moderate)
= 51 to 75% Improvement (Significant)
= 76 to 100% Improvement (Very Significant)
6 weeks
See also
  Status Clinical Trial Phase
Completed NCT03276936 - A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea Phase 3
Completed NCT02601963 - Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea Phase 2
Completed NCT01555463 - Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea Phase 3
Active, not recruiting NCT03667222 - Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea Phase 2
Terminated NCT03564145 - A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Phase 3
Completed NCT05150587 - Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea Phase 2
Completed NCT03263273 - Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea Phase 2
Completed NCT05343455 - A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) Phase 3
Completed NCT01872715 - Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Phase 4
Completed NCT01784133 - A Twelve Week Safety and Efficacy Study in Rosacea Phase 2
Completed NCT05296629 - A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. Phase 3
Completed NCT05838170 - Study of TP-04 in Participants With Papulopustular Rosacea Phase 2
Recruiting NCT06013371 - PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea Phase 2
Recruiting NCT03864978 - Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test Phase 2
Completed NCT03564119 - A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea Phase 3
Completed NCT03079531 - Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea Phase 1/Phase 2
Completed NCT01045551 - Open Label Pilot Study of Apremilast in Treatment of Rosacea Phase 2
Completed NCT03448939 - A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Phase 3
Completed NCT05675501 - Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties Phase 1
Withdrawn NCT03883945 - A Safety and Efficacy Study to Evaluate Rosacea Phase 1/Phase 2